ライフサイエンスコーパス: pegylated

1 lated 4 showed some improvements over the un-PEGylated (18)F-FBA-A20FMDV2 (1), it was the bi-terminal

2 odification with polyethylene glycol to form PEGylated (198)Au-GNPs.

3 Although the C-terminally PEGylated 4 showed some improvements over the un-PEGylat

4 F-FBA-A20FMDV2 (1), it was the bi-terminally PEGylated 5 that displayed the more favorable combinatio

5 ible polymer (ABP)-PEG-HCBP1, by conjugating PEGylated ABP with HCBP1 peptides which has high affinit

6 sing hydrophilic auristatin drug linkers and PEGylated ADCs that yield uniform, high-DAR ADCs with su

7 urthermore, treatment of wild-type mice with pegylated adenosine deaminase or CD73 antibodies also si

8 The efficacy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-ri

9 Biodistribution of the PEGylated agent shows observable fluorescence in xenogra

10 esis of a novel library of propargylated and PEGylated alpha-hydroxy acids toward the preparation of

11 data indicate that the liposomes, which are PEGylated and negatively charged, remain intact at the i

12 ated for different internal standards, i.e., PEGylated and polyhistidine-tagged proteins.

13 ulations of various PAs, (ii) development of PEGylated and targeted liposomal PAs, (iii) physico-chem

14 rgeted specificity than their homologous non-PEGylated anionic and cationic counterparts.

15 geting peptides that act as a bridge between PEGylated anionic liposomes and plasmid DNA.

16 We have developed novel PEGylated, anionic nanocomplexes containing cationic tar

17 A (89)Zr-labeled PEGylated anti-CD8 VHH detected thymus and secondary lym

18 he factors that affect the residence time of PEGylated antibody fragments in the lungs following pulm

19 effect of plasma arginine deprivation using pegylated arginine deiminase (ADI-PEG 20) against primar

20 Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essen

21 targetable by the arginine-degrading enzyme pegylated arginine deiminase (ADI-PEG 20).

22 trategy to exploit arginine deprivation with pegylated arginine deiminase (ADI-PEG20) as a therapeuti

23 The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been ev

24 The Arg-degrading recombinant protein, pegylated arginine deiminase (ADI-PEG20), has been in cl

25 men C) included an additional eight doses of pegylated asparaginase, 18 doses of vincristine, and esc

26 tion and clearance profiles of virtually any PEGylated biomacromolecule from biological fluid samples

27 The study identified a nanomolar potent PEGylated bis-sulfonamide CA inhibitor (25) able to sign

28 fection but reduced TLR9 expression, whereas pegylated bisacycloxypropylcysteine (BPPcysMPEG; TLR2-TL

29 ytosis pathways and biological activities of PEGylated BP nanosheets in cancer cells are revealed for

30 nse combined therapy strategy is achieved by PEGylated BP nanosheets, showing a promising and enhance

31 uantify the blood clearance of (13)C-PEG and PEGylated-BSA (bovine serum albumin) following their int

32 en atom transfer (1,5-HAT) in the decay of a PEGylated carbazyl (aminyl) radical in solution.

33 We used the same pegylated cationic (PCat)-siRNA lipoplexes as in the int

34 Here, we have shown that administration of PEGylated CBS into the circulation of homocystinuria mod

35 RT for a metabolic disorder and suggest that PEGylated CBS should be further explored for use in pati

36 ysteine and the normalization of cysteine in PEGylated CBS-treated model mice were accompanied by imp

37 High levels of uptake of PEGylated-CH1055 dye were observed in brain tumours in m

38 Herein we describe a PEGylated colistin prodrug whereby the PEG is attached v

39 Moreover, PEGylated ConA maintained the ability to track glucose c

40 ounts and ratios of core-forming polymers to PEGylated corona-forming polymers.

41 de range of biocompatible, thermo-responsive PEGylated diblock copolymer nano-objects for various bio

42 were tested as core-forming units, and both PEGylated, diblock polymers were screened as corona-form

43 of (18)F- FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) and at

44 of (18)F- FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) in par

45 hat (18)F- FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) is a s

46 and (18)F- FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) PET/CT

47 had (18)F- FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) uptake

48 wed (18)F- FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) uptake

49 It is found that PEGylated DNA experiences two opposing effects: local ex

50 PEG) and PEGylated molecules is critical for PEGylated drug development.

51 nosis, image-guided surgery, and theranostic PEGylated drug therapies.

52 uals who have never undergone treatment with PEGylated drugs but most likely have been exposed to PEG

53 These PEGylated drugs have longer half-lives in the bloodstrea

54 urvival did not improve likely, because this pegylated enzyme does not enter hepatocytes and does not

55 Pegylated Escherichia coli asparaginase (PEG-asparaginas

56 ed the efficacy of very prolonged courses of pegylated Escherichia coli asparaginase (PEGasparaginase

57 FR104 is a monovalent pegylated Fab' Ab, antagonist of CD28, under development

58 head assessment of FR104 (n=5), a selective pegylated Fab' antibody fragment antagonist of CD28 that

59 anisms involved in the prolonged presence of PEGylated Fab' in the airway lumen might include binding

60 Despite reduced immunogenicity of the pegylated form in comparison with native interferon (IFN

61 A PEGylated form of CBS provided long-term stability and,

62 Pegaspargase (SS-PEG), a pegylated form of Escherichia coli L-asparaginase with a

63 ients with cancer by the administration of a pegylated form of the catabolic enzyme arginase I (peg-A

64 In vitro, a PEGylated form of the peptide, named BNZ132-1-40, reduce

65 I) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue

66 ed ATG (2.5 mg/kg intravenously) followed by pegylated G-CSF (6 mg subcutaneously every 2 weeks for 6

67 tion 4-24 months) were randomized to ATG and pegylated G-CSF (ATG+G-CSF) (N = 17) or placebo (N = 8).

68 labeled DNA-probe strands are immobilized on PEGylated gold nanoparticles (AuNPs).

69 quantification, and ex vivo visualization of PEGylated gold nanoparticles (GNPs) in animals, organs a

70 Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF)

71 f low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte CSF (G-CSF) would preserve beta ce

72 dulatory agents, anti-thymocyte globulin and pegylated granulocyte CSF, neither of which have shown b

73 We find that PEGylated graphene oxide nanosheets (nGO-PEGs) stimulate

74 We tested whether one of these enzymes, a pegylated human recombinant arginase 1 (AEB1102), reduce

75 BCT-100, a pegylated human recombinant arginase, leads to a rapid d

76 FR104 is a monovalent, PEGylated-humanized Fab' Ab fragment against human CD28,

77 TLRs in HCV genotype 1 patients who received pegylated IFN (PEG-IFN) plus ribavirin (RBV) therapy.

78 nvestigated whether DAPK plays a role in the pegylated IFN-alpha (peg-IFN-alpha)-induced antiviral ac

79 rom localized inflammatory skin reactions at pegylated IFN-alpha injection sites, were analyzed for t

80 with sequential treatment of Entecavior and PEGylated IFN-alpha were recruited.

81 atment naive patients, patients treated with PEGylated IFN-alpha, and patients with sequential treatm

82 ls with chronic HCV treated with combination pegylated IFN-alpha, ribavirin, and telaprevir/boceprevi

83 A subset of patients suffering from pegylated IFN-alpha-associated exanthemas displayed posi

84 Skin biopsies obtained from pegylated IFN-alpha-associated exanthemas, as well as fr

85 gate the immunological mechanisms underlying pegylated IFN-alpha-induced drug eruptions.

86 e cutaneous reactions has been reported with pegylated IFN-alpha.

87 HCV RNA more than 6 months after completing pegylated IFN-alpha/ribavirin therapy.

88 Subjects were tested for sensitivity to pegylated IFN-alpha2a , pegylated IFN-alpha2b , or ribav

89 d for sensitivity to pegylated IFN-alpha2a , pegylated IFN-alpha2b , or ribavirin using intradermal,

90 observation correlated with the presence of pegylated IFN-specific T cells (3/11).

91 9860 IL28B genotype, and in vivo response to pegylated IFN/ribavirin therapy.

92 on with high CE and current density in these PEGylated IL media.

93 sed to characterize Mg(2+) speciation in the PEGylated ILs and BMPyrTFSI containing Mg(BH4)2 by study

94 the organic pyrrolidinium cation of the ILs (PEGylated ILs), were prepared that facilitate reversible

95 electrodeposition processes in two specific PEGylated-ILs were compared against that in the widely s

96 ation study, we used a next-generation, mono-pegylated interferon (IFN) alpha-2b isoform, ropeginterf

97 Pegylated interferon (IFN) has been used to treat chroni

98 hronically infected by HCV, and treated with pegylated interferon (IFN)/ribavirin or more-efficacious

99 efficacy and safety of sofosbuvir (SOF) plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in pa

100 er transplantation (LT), and the response to pegylated interferon (PEG-IFN) and ribavirin (RBV) is po

101 Retreatment with pegylated interferon (peg-IFN) and ribavirin (RBV) resul

102 5A-based therapy with daclatasvir (DCV) plus pegylated interferon (Peg-IFN) and ribavirin (RBV), with

103 type 1 (GT1) patients were administered with pegylated interferon (Peg-IFN) and/or ribavirin (RBV), w

104 r (SOF) plus ribavirin (RBV) with or without pegylated interferon (Peg-IFN) do not have established r

105 We investigated whether adding on pegylated interferon (Peg-IFN) to ETV therapy enhances s

106 rials, triple therapy with telaprevir (TVR), pegylated interferon (Peg-IFN), and ribavirin (RBV) achi

107 The introduction of pegylated interferon (PEG-IFN)-alpha in the treatment of

108 ard, which included antiviral treatment with pegylated interferon (Peg-IFN)-based therapies as well a

109 y are associated with treatment responses to pegylated interferon (PEG-IFN)-based therapy in patients

110 ial: N=333, 21% cirrhosis) and SOF, RBV, and pegylated interferon (Peg-IFN; NEUTRINO trial: N=327, 17

111 Pegylated interferon (peginterferon) alfa 2a or 2b plus

112 ease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin

113 fections who had previously not responded to pegylated interferon (peginterferon) and ribavirin or we

114 Subcutaneous pegylated interferon (peginterferon) beta-1a is being de

115 with cirrhosis or previous null response to pegylated interferon (peginterferon) plus ribavirin (PR-

116 me was performed on 11 entecavir-treated and pegylated interferon (peginterferon)-treated patients.

117 best available therapy group), interferon or pegylated interferon (ten [13%] of 75), pipobroman (five

118 imeprevir +/- ribavirin (RBV), n = 53; SOF + pegylated interferon + RBV, n = 25; SOF + RBV, n = 36; a

119 1 should receive treatment with sofosbuvir + pegylated interferon + ribavirin because of the shorter

120 Simeprevir + pegylated interferon + ribavirin is an alternative for p

121 Treatment-experienced (prior interferon or pegylated interferon +/- ribavirin or sofosbuvir plus ri

122 Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir

123 ving NA therapy and 86 patients treated with pegylated interferon alfa (Peg-IFN) and adefovir.

124 Pegylated interferon alfa (PEG-IFNalpha) is effective in

125 Telaprevir, combined with pegylated interferon alfa and ribavirin, is an efficacio

126 V DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks.

127 INTERPRETATION: Pegylated interferon alfa-2a can induce durable haematol

128 ssed the safety and efficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HB

129 Pegylated interferon alfa-2a induced haematological (66

130 Pegylated interferon alfa-2a is an immunomodulatory agen

131 ntravenous REP 2139 and 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks,

132 for 15 weeks, then monotherapy with 180 mug pegylated interferon alfa-2a once per week for 33 weeks.

133 INTERPRETATION: Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well toler

134 The initial starting dose of pegylated interferon alfa-2a was 450 mug subcutaneously

135 ess than <1 IU/mL before the introduction of pegylated interferon alfa-2a.

136 received simeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for

137 trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients

138 This is not the case for pegylated interferon alpha (IFN-alpha)-induced neutropen

139 Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA neg

140 minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon alpha (Peg-IFNalpha 2a) to target J

141 or of p53-MDM2, both alone and combined with pegylated interferon alpha 2a (Peg-IFNalpha 2a), signifi

142 elopment of the NLEM decided to include both pegylated interferon alpha 2a and alpha 2b into the NLEM

143 (QALYs) comparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin

144 Therefore, this research determined whether pegylated interferon alpha 2a or alpha 2b plus ribavirin

145 HCV treatment with pegylated interferon alpha 2a or alpha 2b plus ribavirin

146 Pegylated interferon alpha 2a, alpha 2b and ribavirin ha

147 ceived different antiviral therapy regimens (pegylated interferon alpha 2b and ribavirin different do

148 s with acute HCV treated with 24-48 weeks of pegylated interferon alpha and ribavirin, 15 failed to a

149 virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNalpha/r

150 We conducted a short-course (4 weeks) of pegylated interferon alpha-2a (Peg-IFN-alpha2a) plus rib

151 tic properties of TG4040 in combination with pegylated interferon alpha-2a and ribavirin (PEG-IFNalph

152 chieved SVR after successive treatments with pegylated interferon and protease-inhibitor regimens at

153 Compared to treatment with pegylated interferon and ribavirin (PR), and a protease

154 C virus (HCV) infection includes the use of pegylated interferon and ribavirin as primary components

155 A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were

156 contrast, the historical cohort treated with pegylated interferon and ribavirin experienced only 10%

157 egimens and historical controls treated with pegylated interferon and ribavirin in a single health ca

158 who had failed treatment with >/= 4 weeks of pegylated interferon and ribavirin plus either boceprevi

159 ith cirrhosis and for nonresponders to prior pegylated interferon and ribavirin therapy.

160 ustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher

161 Randomisation was stratified by previous pegylated interferon and ribavirin treatment experience

162 (AGATE-I), treatment-naive and interferon or pegylated interferon and ribavirin treatment-experienced

163 s eradication, but conventional therapy with pegylated interferon and ribavirin yields approximately

164 nt threshold (67%; based on SVR reported for pegylated interferon and ribavirin) to achieve superiori

165 No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy w

166 bavirin has been replaced by sofosbuvir plus pegylated interferon and ribavirin, and all-oral therapi

167 For genotype 6, sofosbuvir plus pegylated interferon and ribavirin, sofosbuvir plus ledi

168 tients who did not respond to treatment with pegylated interferon and ribavirin.

169 reatment-naive or treatment-experienced with pegylated interferon and ribavirin.

170 higher than historical controls treated with pegylated interferon and ribavirin; patients with glomer

171 n combination with ribavirin with or without pegylated interferon in subjects with chronic HCV infect

172 etectable hepatitis C virus (HCV) RNA during pegylated interferon plus ribavirin (peg-IFN/RBV) therap

173 tment-experienced) patients who had received pegylated interferon plus ribavirin all received the rib

174 Pegylated interferon plus ribavirin has been replaced by

175 s and implications in treatment responses to pegylated interferon plus ribavirin treatment (PegIFN/RB

176 Pegylated interferon plus ribavirin treatment was admini

177 HCV genotype 3 and cirrhosis who had failed pegylated interferon plus ribavirin, in 25 of 28 (89%) p

178 eceive combination therapy with both NUC and pegylated interferon remain unsettled.

179 The current nucleos(t)ide analogue (NUC) and pegylated interferon therapies effectively help slow dis

180 - ribavirin or sofosbuvir plus ribavirin +/- pegylated interferon therapy) patients without cirrhosis

181 Investigators could add pegylated interferon to the regimen at their discretion.

182 ot responded to treatment with interferon or pegylated interferon with or without ribavirin, or sofos

183 e treatment experienced, whereas sofosbuvir, pegylated interferon, and ribavirin for 12 weeks is an a

184 tudy of combination therapy with telaprevir, pegylated interferon, and ribavirin in acute genotype 1

185 t the maximum tolerated dose], interferon or pegylated interferon, pipobroman, anagrelide, approved i

186 ceived previous treatment with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combin

187 rt of 200 Egyptian CHC patients treated with Pegylated interferon-alpha (Peg-IFN) plus ribavirin.

188 considered difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-alpha) and ribavirin

189 The use of pegylated interferon-alpha (pegIFN-alpha) has replaced u

190 We studied the antiviral potency of pegylated interferon-alpha (pegIFNalpha) against HEV inf

191 of chronic HCV infection in combination with pegylated interferon-alpha and ribavirin in Japan, Canad

192 genotype 1b infection and a null response to pegylated interferon-alpha and ribavirin who developed d

193 nosuppression or treatment with ribavirin or pegylated interferon-alpha can result in viral clearance

194 After 4 weeks of pegylated interferon-alpha-2a/ribavirin (PEGIFN/RBV) lea

195 -boost regimen, with and without concomitant pegylated interferon-alpha/ribavirin therapy.

196 ith cirrhosis, and/or prior nonresponders to pegylated interferon-based regimens.

197 Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy.

198 come of retreatment with SOF, ribavirin, and pegylated interferon.

199 retreatment outcome with SOF, ribavirin, and pegylated interferon.

200 or sofosbuvir plus ribavirin with or without pegylated interferon.

201 kidney transplant, and 82% previously failed pegylated interferon/RBV-based regimens) received treatm

202 Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown

203 HCV genotype 1 patients receiving telaprevir/pegylated interferon/ribavirin in OPTIMIZE were analyzed

204 of care, sofosbuvir/simeprevir or sofosbuvir/pegylated interferon/ribavirin, was included for compari

205 evels in 15 patients treated with telaprevir/pegylated interferon/ribavirin.

206 he direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV)

207 genotype 1 HCV treated with telaprevir (TVR)/pegylated-interferon alpha/ribavirin.

208 irin, 87.0% in patients given sofosbuvir and pegylated-interferon plus ribavirin, and 70.6% of patien

209 rom 10 patients during the first 28 weeks of pegylated-interferon-alpha2a (peg-IFN) therapy.

210 ptions in association with administration of pegylated interferons were enrolled in the study (n = 22

211 spanning three different biomaterial types, pegylated lipid nanocapsules, polyvinyl acetate (PVAc) a

212 Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect thi

213 merging vesicles made from synthetic lipids (PEGylated lipids and POPC lipids) with native cell-membr

214 been observed that under certain conditions PEGylated lipids induce humoral immunity.

215 e results reveal the necessity of having the PEGylated lipids present during vesicle adsorption to pr

216 nce it was originally thought that synthetic PEGylated lipids were immunologically inert; however, it

217 Since pegylated liposomal doxorubicin (PLD) was the most preva

218 After investigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or t

219 However, recent reports show that certain pegylated liposomal nanoparticles (PLNs) and polymeric n

220 icin (DOX)] and an 80-nm chemotherapy-loaded pegylated liposome (DOX-PLD) in tumor vasculature.

221 Here, we demonstrate a novel PEGylated liposome system, named DAFODIL (Doxorubicin An

222 MM-302 is a HER2-targeted PEGylated liposome that encapsulates doxorubicin to faci

223 lethylenediamine (BMEDA) and loaded into the PEGylated liposome to form a (188)Re-liposome.

224 and bioluminescent imaging suggest that the PEGylated liposome-embedded (188)Re could be used for th

225 kinetics of doxorubicin (DOX), delivered by pegylated liposomes (PLD), to murine lung (3LL) and brea

226 n half-life of the 3HM was similar to 110-nm PEGylated liposomes (t1/2=15.5 and 16.5h, respectively),

227 The siRNA carrier was pegylated liposomes comprising cationic and neutral lipi

228 PEGylated liposomes have transformed chemotherapeutic us

229 posomal distribution in vivo by injection of pegylated liposomes radiolabeled with (111)In.

230 Gylated liposomes with short-circulating non-PEGylated liposomes showed much higher accumulation of P

231 liposomes showed much higher accumulation of PEGylated liposomes that persisted several days after th

232 ccumulation of DiR labeled, long-circulating PEGylated liposomes with short-circulating non-PEGylated

233 PEGylated liposomes with varying ratios of the targeting

234 also showed higher silencing efficiency than PEGylated LYR-P and LER-P nanoparticles.

235 nding capacity of 293T/SL-alphaPEG cells for PEGylated macromolecules was higher than that of 293T/S-

236 elop anti-PEG antibody during treatment with PEGylated medicines, suggesting that genetics might play

237 ive determination of the pharmacokinetics of PEGylated molecules can accelerate the process of drug d

238 okinetics of poly(ethylene glycol) (PEG) and PEGylated molecules is critical for PEGylated drug devel

239 capacity method for quantifying free PEG and PEGylated molecules.

240 apacity and detection limit for free PEG and PEGylated molecules.

241 nt tool for the quantification of a range of PEGylated molecules.

242 f PEGylation on MTX loading was observed but PEGylated MSNR (PMSNR) demonstrated increased MTX releas

243 Anionic PEGylated nanocomplexes were resistant to aggregation in

244 omaterials but also suggest applications for PEGylated nanomaterials wherein immune stimulation is de

245 sts that polyethylene glycol-functionalized (PEGylated) nanomaterials are largely biocompatible and e

246 We prove for the first time that PEGylated nanoparticles evade major brain cell populatio

247 usly injected nanopharmaceuticals, including PEGylated nanoparticles, induce adverse cardiopulmonary

248 with 15-2b are more suitable for quantifying PEGylated nanoparticles.

249 60 lung cancer and AsPC-1 pancreatic cancer, pegylated NCPs show superior potency and efficacy compar

250 Here we report the development of PEGylated-NHC ligands for Au-NP surfaces and the first e

251 Our PEGylated-NHC-Au-NPs are stable toward aggregation in aq

252 e lead formulation, DB4-PDB12, was optimally PEGylated not only to ensure colloidal stability (no cha

253 injury received an intravenous injection of PEGylated NP cocktail (20, 40, 100, and 500 nm, each wit

254 revealed that Abraxane, an FDA-approved non-PEGylated NP formulation used for cancer therapy, binds

255 eted nanomedicine, rapamycin encapsulated in pegylated octadecyl lithocholate micelles labeled with a

256 rs) compared to cisplatin in conventional un-PEGylated particles (median survival=40days), cisplatin

257 ted the first comparative study of uptake of PEGylated particles by all the major (immune and non-imm

258 ce within the brain, the mode of handling of PEGylated particles by the resident immune cells of the

259 Conversely, the drug loading in non-PEGylated particles was better (20wt.%), but the PK was

260 of conjugated particles was evaluated versus PEGylated particles, and PNB conjugation demonstrated th

261 trated increased MTX release compared to non-PEGylated particles.

262 (>90% positive cells) than the most densely PEGylated particles.

263 dded the therapeutic radionuclide (188)Re in PEGylated (PEG is polyethylene glycol) liposomes and inv

264 BV pretreatment, who all received subsequent pegylated (Peg)IFN/ribavirin combination therapy.

265 ed of nanostructured lipid carrier (NLC) and PEGylated poly(amidoamine) dendrimer (PEG-PAMAM).

266 er therapeutic carriers such as FDA approved pegylated poly(lactic-co-glycolic acid) nanoparticles (P

267 blend of polyaspartic acid (PAA) and heavily PEGylated polyaspartic acid (PAA-PEG), was highly stable

268 that end we have developed long-circulating, PEGylated, polymeric hydrogels using the Particle Replic

269 Both (40K)PEG and a tool PEGylated protein (ATI-1072) underwent dissociation in t

270 y higher sensitivity for quantification of a PEGylated protein (PegIntron) and multiarm PEG macromole

271 thod to assess PEG biodistribution following PEGylated protein administration, a single dose study of

272 ssue homogenates suggests the degradation of PEGylated proteins after dose administration to rats, gi

273 vercome these shortcomings, and more than 10 PEGylated proteins have been brought to market.

274 tivity for free PEG, PEG-like molecules, and PEGylated proteins with detection at ng mL(-1) levels.

275 a growing number of marketed products (e.g. PEGylated proteins, a PEG-aptamer and oral polymeric seq

276 ication of free PEG, PEG-like molecules, and PEGylated proteins, whereas the 293T/3.3 cells combined

277 of the PEG moiety after repeated dosing with PEGylated proteins.

278 characterization of disposition and fate of PEGylated proteins.

279 64.6 +/- 13.7%) interacted with administered PEGylated quantum dots, but splenic macrophages took up

280 The PEGylated Rab proteins undergo normal prenylation, under

281 The bi-PEGylated radiotracer 5 showed a greatly improved pharma

282 nstrate further that systemic treatment with pegylated recombinant hyaluronidase (PEGPH20) depletes i

283 Clearance of PEGylated rFVIII, rFVIIIFc, and rVIII-SingleChain is sti

284 human granulocyte-colony stimulating factor (PEGylated rhG-CSF or pegfilgrastim), by electrospray ion

285 We used (89)Zr-labeled PEGylated single-domain antibody fragments (VHHs) specif

286 1)H NMR spectroscopy can be used to quantify PEGylated species in complex biological fluids directly,

287 For the best dimer, which contained a pegylated squaraine core, we obtained a very high turn-o

288 The probe derived from the core-pegylated squaraine showed the highest specificity to th

289 several clinical reports examining different PEGylated therapeutics.

290 t raise serious concerns about the future of PEGylated therapeutics.

291 ng the immunogenicity of PEG and efficacy of PEGylated therapeutics.Some individuals develop antibodi

292 More importantly, pegylated TNT-b10 LLNs is stable for over four weeks and

293 with very small mesh size, and subsequently PEGylated to quench the exterior amines only without aff

294 ) extending the half-life of the ligand with PEGylated TRAIL (TRAILPEG) and (2) concentrating a TRAIL

295 emically administering a potent, long-acting PEGylated TRAIL (TRAILPEG) is profoundly anti-rheumatic

296 -bearing mice with polyethylene glycolyated (PEGylated) type-I interferon-alpha2b reduces the express

297 nistration of tolerogenic nanoparticles with pegylated uricase inhibited the formation of ADAs in mic

298 monstrate the efficacy of the brain-permeant PEGylated version of the anti-solTNF peptide, XPro1595,

299 We report the synthesis and kinetic study of PEGylated, water-soluble aminyl radical 2.

300 circumvent this, we prepared (19)F labeled, PEGylated, water-soluble dendritic nanoparticles with a